Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a buy right now? Hedge funds are getting more bullish. The number of long hedge fund positions improved by 1 in recent months.
In the financial world, there are many methods shareholders can use to analyze the equity markets. Some of the most under-the-radar are hedge fund and insider trading movement. At Insider Monkey, our studies have shown that, historically, those who follow the top picks of the elite investment managers can beat the S&P 500 by a solid margin (see just how much).
Just as important, optimistic insider trading sentiment is a second way to break down the financial markets. Obviously, there are lots of reasons for an executive to sell shares of his or her company, but only one, very simple reason why they would initiate a purchase. Many academic studies have demonstrated the useful potential of this strategy if investors understand what to do (learn more here).
Keeping this in mind, it’s important to take a look at the latest action surrounding Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Hedge fund activity in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
At year’s end, a total of 17 of the hedge funds we track were bullish in this stock, a change of 6% from the third quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were increasing their holdings substantially.
According to our comprehensive database, Jérôme Pfund and Michael Sjöström’s Sectoral Asset Management had the largest position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN), worth close to $59 million, accounting for 2.1% of its total 13F portfolio. Coming in second is Donald Chiboucis of Columbus Circle Investors, with a $54 million position; 0% of its 13F portfolio is allocated to the company. Some other hedgies that hold long positions include Christopher MedlockáJames’s Partner Fund Management, and Samuel Isaly’s OrbiMed Advisors.
As aggregate interest increased, specific money managers have been driving this bullishness. Renaissance Technologies, managed by Jim Simons, established the biggest position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Renaissance Technologies had 16 million invested in the company at the end of the quarter. Phill Gross and Robert Atchinson’s Adage Capital Management also made a $9 million investment in the stock during the quarter. The other funds with new positions in the stock are Malcolm Fairbairn’s Ascend Capital, D. E. Shaw’s D E Shaw, and Ken Griffin’s Citadel Investment Group.
How are insiders trading Regeneron Pharmaceuticals Inc (NASDAQ:REGN)?
Insider buying is at its handiest when the primary stock in question has experienced transactions within the past half-year. Over the latest six-month time period, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has seen zero unique insiders buying, and 16 insider sales (see the details of insider trades here).
With the results exhibited by Insider Monkey’s research, everyday investors should always watch hedge fund and insider trading activity, and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is no exception.
Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.